The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Genetic evaluation of fatigue in pazopanib-treated patients (pts) with advanced renal cell carcinoma (RCC).
S. M. Glass
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
L. Huang
Research Funding - GlaxoSmithKline
K. King
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
L. J. Ragone
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Research Funding - GlaxoSmithKline
H. A. Ball
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
P. L. De Souza
Consultant or Advisory Role - GlaxoSmithKline
J. Wagstaff
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
C. F. Spraggs
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
V. E. Mooser
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
L. N. Pandite
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
C. Xu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline